UCB S.A.

UCB S.A. is a global biopharmaceutical company that focuses on developing innovative medicines and sustainable solutions for patients living with severe diseases. Specializing particularly in the fields of neurology and immunology, UCB S.A. aims to improve the life quality of people with conditions such as epilepsy, Parkinson’s disease, Crohn’s disease, and rheumatoid arthritis. Based in Brussels, Belgium, the company leverages cutting-edge biotechnology to discover novel therapeutic solutions. UCB S.A. operates research facilities across multiple continents, facilitating a deep investment in pioneering scientific research and development. The company's products are marketed worldwide through sales channels in North America, Europe, and emerging markets, making it a significant player in the global healthcare industry. By maintaining a portfolio that includes both established medications and promising pipeline candidates, UCB S.A. positions itself as a leader in addressing unmet medical needs and advancing healthcare innovation. The company's commitment to medical research and its collaborative approach with patient communities underscore its role in enhancing patient-centric care and contributing to the global push for innovative healthcare solutions.